Background Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of
acute myeloid leukemia (AML). We evaluated efficacy and safety of a chemotherapy including …

… However, when administered to elderly patients with newly diagnosed AML or myelodysplasia,
GO did not seem superior to standard idarubicin combined with cytosinearabinoside [78]. …

… However, in elderly patients with newly diagnosed AML or myelodysplasia, GO was compared
to standard idarubicin combined with cytosine–arabinoside, GO did not seem superior [90]…

… Gemtuzumab ozogamicin (GO) is the only new agent approved for treatment of the vast
majority of AML patients, including ND-AML and RR-AML disease in adults and RR-AML in …

… and cytosine arabinoside (… gemtuzumab ozogamicin in the US, particularly striking results
were obtained, with 4/40 patients surviving for over 44 months. 33 Gemtuzumab ozogamicin …

… [11] Cardiotoxicity, particularly with anthracyclines and mitoxantrone,[11] and neurotoxicity
after high-dose cytarabine (cytosine arabinoside, ara-C) also occur more frequently in elderly …

… The Southwest Oncology Group (SWOG) is carrying out a randomized study in which GO is
added to a conventional cytosine arabinoside and daunorubicin induction regimen. Patients …

… Gemtuzumab ozogamicin is an antibody conjugate of … Gemtuzumab ozogamicin has shown
significant activity in … (CR) rate of 84% with gemtuzumab ozogamicin vs. 55% without has …

… superiority of adding new cytotoxic agents to cytosine arabinoside (ara-C) and anthracycline-…
has been with gemtuzumab ozogamicin, an immunoconjugate that binds the CD33 antigen. …

… gemtuzumab ozogamicin resistance is poorly defined. In this study, blast cell samples from
relapsed AML patients eligible for gemtuzumab ozogamicin … In vitro gemtuzumab ozogamicin–…